A global grant empowering cutting-edge myeloma research. Provides substantial funding for investigator-initiated translational projects that advance prevention, diagnosis, or treatment of plasma cell disorders . Emphasizes innovation and invites even non-myeloma scientists to pivot their expertise to myeloma.
Eligibility Criteria:
- Established MD and/or PhD researchers worldwide (no geographic restrictions) .
- Must hold an independent research position; encourages refocusing existing expertise on myeloma research.
- Proposal should have clear potential to improve outcomes in plasma cell dyscrasias (multiple myeloma and related conditions).
Funding Details:
- Amount/Duration: Up to $175,000–$250,000 USD total for a 2-year project .
- Use of Funds: Direct research costs (personnel, lab supplies, etc.).
- Administered by the International Myeloma Society (IMS) and the Riney Foundation. Project start: 2026.
Deadline:
- January 30, 2026 – Full proposal due (single-stage application).
- Late January 2026 deadline allows projects to commence by mid-2026.
Where to go for further information:
- Program details.